FDA Approves Polypill Widaplik for Hypertension
By Lori Solomon HealthDay Reporter
WEDNESDAY, June 11, 2025 -- The U.S. Food and Drug Administration has approved Widaplik (telmisartan, amlodipine, and indapamide) for the treatment of hypertension in adults.
The combination pill is the first and only FDA-approved triple combination medication for use as an initial therapy in patients who will likely need multiple drugs to achieve their ideal blood pressure numbers. The pill is available in a standard dose, as well as two low doses, and can be used in those initiating treatment.
The FDA approval is based on positive results from two international phase 3 trials that compared Widaplik to dual combinations of its component drugs as well as to placebo. The results of both trials indicated that Widaplik significantly improved blood pressure control compared with the comparators.
The most common adverse event reported in patients treated with Widaplik was symptomatic low blood pressure. Additionally, Widaplik is contraindicated in patients with anuria or known hypersensitivity to other sulfonamide-derived drugs. Widaplik is not to be coadministered with aliskiren in patients with diabetes, and a boxed warning indicates discontinuation of Widaplik during pregnancy.
"I am very excited and pleased to have Widaplik approved for the treatment of hypertension in the U.S. Single-pill combination antihypertensive therapy has great potential to improve hypertension control in the U.S. and worldwide," Paul Whelton, M.D., of Tulane University in New Orleans and past president of the World Hypertension League, said in a statement. "Most patients with hypertension need multiple therapies to achieve their blood pressure goals. The new dose options available with Widaplik offer a treatment regimen that could benefit a broad range of patients, including those just starting treatment."
The approval of Widaplik was granted to George Medicines.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted June 2025
Read this next
Doctors Overlooking Common Cause Of High Blood Pressure, New Guidelines Say
WEDNESDAY, July 16, 2025 — Doctors are regularly overlooking a common hormone-driven cause of high blood pressure, a new paper warns. As many as 30% of high blood pressure...
1970 to 2022 Saw Decrease in Overall Heart Disease Mortality
TUESDAY, July 1, 2025 -- From 1970 to 2022, there was a decrease in heart disease mortality overall, but an increase in mortality from other heart conditions, including heart...
Eli Lilly to Buy Gene Therapy Firm Verve in $1 Billion Deal to Develop Heart Drug
WEDNESDAY, June 18, 2025 — Drugmaker Eli Lilly plans to buy Verve Therapeutics, a gene-editing startup, for about $1 billion upfront. The deal gives Lilly a potential...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.